Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-05-22 | Dr. Kenneth C. Froewiss, 71 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2014); Member, Finance Committee, Association for Asian Studies (2002-present); Director, Mitsui Sumitomo Insurance Group (US) (2004-present); formerly, Managing Director, J.P. Morgan (investment banking firm) (until 1996). |
| 2018-05-09 | Dr. Kenneth C. Froewiss, 72, Retired Clinical Professor of Finance, NYU Stern School of Business ... Continuing Class II Director for CEE since 2017, Continuing Class III Director for EEA since 2017, Continuing Class II Director for GF since 2017 ... The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister ... The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister ... The following table sets forth the aggregate compensation ... Dr. Froewiss: $1,219 (CEE), $2,528 (EEA), $9,351 (GF), total $303,099. |
| 2019-05-20 | Dr. Kenneth C. Froewiss, 73 Retired Clinical Professor of Finance... Continuing Class II Director for CEE since 2017 Continuing Class III Director for EEA since 2017 Continuing Class II Director for GF since 2017... The Audit Committee, currently comprising Drs. Froewiss and Pleister... The Nominating and Governance Committee, currently comprising Drs. Froewiss (Chair)... Compensation: $11,411 from EEA, $7,581 from GF, total $48,606 from Fund Complex. |
| 2020-05-15 | Dr. Kenneth C. Froewiss, 74 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2011); Director, Mitsui Sumitomo Insurance Group (US) (2004-present); Chairman of DWS USA Corporation (since March 2018); formerly, Managing Director, J.P. Morgan (investment banking firm) (until 1996); Former Member, Finance Committee, Association of Asian Studies (2002-2017). The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister. The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister. The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2019 for CEE and December 31, 2019 for GF, and (b) the total compensation from the Fund Complex for the 2019 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Kenneth C. Froewiss $18,092 $ 24,368 $ 49,824 |
| 2021-05-14 | Dr. Kenneth C. Froewiss, 75 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2011)... Director of The European Equity Fund, Inc. (since 2017) Continuing Class II Director for CEE since 2017 Continuing Class II Director for GF since 2017 Shares of Common Stock Owned at April 30, 2021: CEE: 577, GF: 918 Audit Committee, Nominating and Governance Committee Aggregate Compensation from Fund Complex: $55,503 |
| Filing Date | Source Excerpt |
|---|---|
| 2017-05-22 | Dr. Kenneth C. Froewiss, 71 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2014); Member, Finance Committee, Association for Asian Studies (2002-present); Director, Mitsui Sumitomo Insurance Group (US) (2004-present); formerly, Managing Director, J.P. Morgan (investment banking firm) (until 1996). Director, Deutsche family of mutual funds (since 2001). Nominee as Class II Director of CEE to serve until the 2020 Annual Meeting. Nominee as Class III Director of EEA to serve until the 2020 Annual Meeting. Nominee as Class II Director of GF to serve until the 2020 Annual Meeting. The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2016 for CEE and December 31, 2016 for EEA and GF, and (b) the total compensation from the Fund Complex for the 2016 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Kenneth C. Froewiss $0 from all Funds. |
| 2018-05-09 | Dr. Kenneth C. Froewiss, 72 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2014); Member, Finance Committee, Association for Asian Studies (2002-present); Director, Mitsui Sumitomo Insurance Group (US) (2004-present); Chairman of Deutsche Asset Management U.S. Holding Company Corporation (since March 2018); formerly, Managing Director, J.P. Morgan (investment banking firm) (until 1996); Director, Deutsche family of mutual funds (2001-March 2018). The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister, operates pursuant to a written charter which is available on the Funds' website. The Audit Committee's organization and responsibilities are contained in the Audit Committee Report, which is included in this Proxy Statement, and in its written charter. The members of the Audit Committee are "independent" as required by the independence standards of Rule 10A-3 under the Securities Exchange Act of 1934. The Board of Directors has determined that each member of the Audit Committee is financially literate and has determined that Mr. Dostmann and Dr. Froewiss meet the requirements for an audit committee financial expert under the rules of the Securities and Exchange Commission ("SEC"). The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2017 for CEE and December 31, 2017 for EEA and GF, and (b) the total compensation from the Fund Complex for the 2017 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Froewiss CEE: $1,219 EEA: $2,528 GF: $9,351 Total: $303,099 All members on each of the five committees of the Board are not "interested persons" as the term is defined in the Investment Company Act, with the exception of Mr. Strenger, who is a member of the Executive Committee and Dr. Leoni, who is a member of the Executive Committee and Valuation Committee. |
| 2019-05-20 | Dr. Kenneth C. Froewiss, 73 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2014); Member, Finance Committee, Association for Asian Studies (2002-present); Director, Mitsui Sumitomo Insurance Group (US) (2004-present); Chairman of DWS USA Corporation (since March 2018); formerly, Managing Director, J.P. Morgan (investment banking firm) (until 1996); Director, DWS family of mutual funds (2001-March 2018). Continuing Class II Director for CEE since 2017 Continuing Class III Director for EEA since 2017 Continuing Class II Director for GF since 2017 The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister, operates pursuant to a written charter which is available on the Funds' website. The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2018 for CEE and December 31, 2018 for EEA and GF, and (b) the total compensation from the Fund Complex for the 2018 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Kenneth C. Froewiss $ 11,411 $ 7,581 $ 29,615 $ 48,606 No compensation is paid by a Fund to Directors who are interested persons of the Fund or of any entity of the Deutsche Bank Group or to officers. |
| 2020-05-15 | The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister... The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister... The following table sets forth (a) the aggregate compensation from the Fund for the fiscal year ended December 31, 2019... Dr. Kenneth C. Froewiss $7,362. |
| 2021-05-14 | The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister... The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister... The following table sets forth (a) the aggregate compensation from the Fund for the fiscal year ended December 31, 2020... Dr. Kenneth C. Froewiss $7,401. |
| Filing Date | Source Excerpt |
|---|---|
| 2017-05-22 | Dr. Kenneth C. Froewiss, 71 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2014); Member, Finance Committee, Association for Asian Studies (2002-present); Director, Mitsui Sumitomo Insurance Group (US) (2004-present); formerly, Managing Director, J.P. Morgan (investment banking firm) (until 1996). |
| 2018-05-09 | Dr. Kenneth C. Froewiss, 72 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2014); Member, Finance Committee, Association for Asian Studies (2002-present); Director, Mitsui Sumitomo Insurance Group (US) (2004-present); Chairman of Deutsche Asset Management U.S. Holding Company Corporation (since March 2018); formerly, Managing Director, J.P. Morgan (investment banking firm) (until 1996); Director, Deutsche family of mutual funds (2001-March 2018). Continuing Class II Director for CEE since 2017 Continuing Class III Director for EEA since 2017 Continuing Class II Director for GF since 2017 CEE: 500 EEA: 1,100 GF: 600 The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister, operates pursuant to a written charter which is available on the Funds' website. The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister, operates pursuant to a written charter which is available on the Funds' website. The following table sets forth (a) the aggregate compensation from each Fund for the fiscal year ended October 31, 2017 for CEE and December 31, 2017 for EEA and GF, and (b) the total compensation from the Fund Complex for the 2017 calendar year, (i) for each Director who is not an interested person of the Funds, and (ii) for all such Directors as a group. Dr. Kenneth C. Froewiss 1,219 2,528 9,351 303,099 |
| 2019-05-20 | Dr. Kenneth C. Froewiss, 73 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2014); Member, Finance Committee, Association for Asian Studies (2002-present); Director, Mitsui Sumitomo Insurance Group (US) (2004-present); Chairman of DWS USA Corporation (since March 2018); formerly, Managing Director, J.P. Morgan (investment banking firm) (until 1996); Director, DWS family of mutual funds (2001-March 2018). Continuing Class II Director for CEE since 2017 Continuing Class III Director for EEA since 2017 Continuing Class II Director for GF since 2017 CEE: 529 EEA: 1,100 GF: 784 The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister, operates pursuant to a written charter which is available on the Funds website, https://fundsus.dws.com/EN/docs/products/Germany-Funds-Audit-Committee-Charter.pdf. The Audit Committees organization and responsibilities are contained in the Audit Committee Report, which is included in this Proxy Statement, and in its written charter. The members of the Audit Committee are 3independent 4 as required by the independence standards of Rule 10A-3 under the Securities Exchange Act of 1934. The Board of Directors has determined that each member of the Audit Committee is financially literate and has determined that Mr. Dostmann and Dr. Froewiss meet the requirements for an audit committee financial expert under the rules of the Securities and Exchange Commission ( 3EC 4). Although the Board has determined that Mr. Dostmann and Dr. Froewiss meet the requirements for an audit committee financial expert, their responsibilities are the same as those of the other audit committee members. Mr. Dostmann and Dr. Froewiss are not auditors or accountants, do not perform 3field work 4 and are not full-time employees. The SEC has stated: (i) that an audit committee member who is designated as an audit committee financial expert will not be deemed to be an 3expert 4 for any purpose as a result of being identified as an audit committee financial expert; and (ii) that the designation or identification of a person as an audit committee financial expert does not: (A) impose on such person any duties, obligations, or liabilities that are greater than those imposed on such persons as members of the audit committee or board of directors in the absence of such designation or identification; or (B) affect the duties, obligations, or liability of any other member of the audit committee or the board of directors. The Audit Committee met four times during each Funds fiscal year ending in 2018. The Advisory Committee, currently comprising Ambassador Burt and Mr. Dostmann (Chair) and Dr. Pleister, makes recommendations to the full Board with respect to the Administration Agreement between each Fund and DWS Investment Management Americas, Inc., and the Investment Advisory Agreement between each Fund and DWS International GmbH. The Advisory Committee met two times during each Funds past fiscal year. The Executive Committee, currently comprising Ambassador Burt and Dr. Leoni and Mr. Strenger, has the authority to act for the Board on all matters between meetings of the Board subject to any limitations under applicable state law. The Executive Committee did not meet during each Funds past fiscal year. The Valuation Committee, currently comprising Drs. Bender and Leoni (Chair), reviews each Funds valuation procedures and makes recommendations with respect thereto and, to the extent required by such procedures, determines the fair value of the Funds securities or other assets. The Valuation Committee met two times during each Funds past fiscal year. The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister, operates pursuant to a written charter which is available on the Funds website, https://fundsus.dws.com/EN/docs/products/Germany-Master-Nominating-Committee-Charter.pdf. The Board has determined that each of the members of the Nominating and Governance Committee is not an 3interested person 4 as the term is defined in Section 2(a)(19) of the Investment Company Act. Generally, the Nominating and Governance Committee identifies, evaluates and selects and nominates, or recommends to the Board of Directors, candidates for the Board or any committee of the Board, and also advises the Board regarding governance matters generally and confirms that the Board and Audit Committee undertake annual self-evaluations. To be eligible for nomination as a Director a person must, at the time of such persons nomination, have Relevant Experience and Country Knowledge and must not have any Conflict of Interest, as those terms are defined in the Funds Bylaws. The relevant portions of each Funds Bylaws describing these requirements are included as Annex A. The Nominating and Governance Committee may also take into account additional factors listed in the Nominating and Governance Committee Charter, which generally relate to the nominees industry knowledge, business experience, education, ethical reputation, special skills, ability to work well in group settings and the ability to qualify as an 3independent director 4. When assessing a candidate for nomination, the Nominating and Governance Committee considers whether the individuals background, skills and experience will complement the background, skills and experience of other nominees and will contribute to the diversity of the Board. The Nominating and Governance Committee met two times during each Funds past fiscal year. The following table sets forth the aggregate compensation from each Fund for the fiscal year ended October 31, 2018 for CEE and December 31, 2018 for EEA and GF, and the total compensation from the Fund Complex for the 2018 calendar year, for each Director who is not an interested person of the Funds, and for all such Directors as a group. Dr. Kenneth C. Froewiss $ 11,411 $ 7,581 $ 29,615 $ 48,606 |
| 2020-05-15 | Dr. Kenneth C. Froewiss, 74 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2011)... Nominee as Class II Director for CEE to serve until the 2023 Annual Meeting. Class II Director for CEE since 2017 Nominee as Class II Director for GF to serve until the 2023 Annual Meeting. Class II Director for GF since 2017 The Audit Committee, currently comprising Ambassador Burt, Mr. Dostmann (Chair), and Drs. Froewiss and Pleister... The Nominating and Governance Committee, currently comprising Ambassador Burt (Deputy Chair) and Drs. Froewiss (Chair) and Pleister... CEE Aggregate Compensation from Fund: $18,092 |
| 2021-05-14 | Dr. Kenneth C. Froewiss, 75 Retired Clinical Professor of Finance, NYU Stern School of Business (1997-2011)... Director of The European Equity Fund, Inc. (since 2017) Continuing Class II Director for CEE since 2017 Continuing Class II Director for GF since 2017 Audit Committee, Nominating and Governance Committee Shares: CEE 577, GF 918 Compensation: GF $27,715 + CEE $18,670 = $55,503 |
Data sourced from SEC filings. Last updated: 2025-12-06